Daewoong Unveiled Breakthrough Diabetes Treatment at ADA Conference
- Pexels/Mikhail Nilov
United States – Daewoong Pharmaceutical presented the combined analysis results from Phase 3 clinical trials of Enavogliflozin, demonstrating significant effectiveness and safety in treating type 2 diabetes at the 84th  American Diabetes Association (ADA) Conference in Orlando, United States last week.
Enavogliflozin is notably effective for patients with mild kidney impairment struggling to control blood glucose levels. The study compared Enavogliflozin, combined with metformin, against dapagliflozin.
The findings reveal that Enavogliflozin provides superior blood glucose control, increases urinary glucose excretion, and significantly improves insulin resistance.
Over the 24-week study period, Enavogliflozin reduced glycated hemoglobin (HbA1c) levels by 0.94 percent, a better result than the 0.77 percent reduction achieved by dapagliflozin.
Korean Pharmaceutical Company, Daewoong
- Daewoong Group
Additional benefits include fasting plasma glucose reduction, increased urinary glucose excretion, and improved insulin resistance.
As information, the ADA Conference is a prestigious event among global healthcare professionals, serving as an ideal platform to introduce Enavogliflozin, the first SGLT-2 inhibitor developed in Korea by Daewoong.
Daewoong Pharmaceutical CEO Chang-jae Lee expressed confidence that Enavogliflozin could gain recognition as a more effective alternative to dapagliflozin.
"This presentation is an opportunity to showcase the advantages of Enavogliflozin to the global healthcare community," he said in a statement on Wednesday (June 26).
Enavogliflozin stands out for its ability to significantly reduce HbA1c at a low dose of 0.3mg, achieving around 70 percent attainment of target blood glucose levels (HbA1c < 7 percent), improving cardiovascular risk factors, and supported by extensive clinical data in Korean patients.
Meanwhile in 2023, Daewoong Pharmaceutical submitted a New Drug Application (NDA) for Enavogliflozin in Indonesia.
As the 36th drug developed domestically in South Korea, Enavogliflozin is projected to become a leading treatment for diabetes due to its impressive results.
Enavogliflozin, administered at only 0.3mg – which is 1/30 of the existing SGLT2 inhibitor doses – has proven equally or even more effective in reducing glycated hemoglobin (HbA1c) and fasting blood glucose levels compared to existing drugs on the market.
